Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia.

ABSTRACT: While the understanding of the genomic aberrations that underpin chronic and acute myeloid leukaemia (CML and AML) has allowed the development of therapies for these diseases, limitations remain. These become apparent when looking at the frequency of treatment resistance leading to disease relapse in leukaemia patients. Key questions regarding the fundamental biology of the leukaemic cells, such as their metabolic dependencies, are still unresolved. Even though a majority of leukaemic cells are killed during initial treatment, persistent leukaemic stem cells (LSCs) and therapy-resistant cells are still not eradicated with current treatments, due to various mechanisms that may contribute to therapy resistance, including cellular metabolic adaptations. In fact, recent studies have shown that

SUBMITTER: de Beauchamp L 

PROVIDER: S-EPMC8727299 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature